

REFERENCES

1. Chang LY, Shih SR, Shao PL, Huang DT, Huang LM. Novel swine-origin influenza virus A (H1N1): the first pandemic of the 21st century. *J Formos Med Assoc.* 2009;108(7):526-32.
2. Sperling W, Biermann T. Influenza H1N1 and the world wide economic crisis--a model of coherence? *Med Hypotheses.* 2009;73(5):664-6.
3. Smith GJD, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. *Nature.* 2009;459:1122-6.
4. Schnitzler SU, Schnitzler P. An update on swine-origin influenza virus A/H1N1: a review. *Virus Genes.* 2009;39(3):279-92.
5. WHO. Influenza A (H1N1) – Update 48. [Online]. 2009. Available from: http://www.who.int/csr/don/2009_06_12/en/ (2 January 2010)
6. WHO. Influenza A (H1N1) – Update 72. [Online]. 2009. Available from: http://www.who.int/csr/don/2009_10_30/en/ (4 January 2010)
7. กระทรวงวิทยาศาสตร์และเทคโนโลยี. ไข้หวัดใหญ่สายพันธุ์ใหม่ 2009 และสถานภาพงานวิจัย. [ระบบออนไลน์]. 2552. แหล่งที่มา: <http://www.most.go.th/main/index.php/services/information-service/785-2009-new-flu-strains> (12 January 2010)

8. Rossignol JF, Frazia SL, Chiappa L, Ciucci A, Santoro MG. Thiazolidines, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. *JBC*. 2009;1-18.
9. Brown EG. Influenza virus genetics. *Biomed Pharmacother*. 2000;54(4):196-209.
10. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. *Nature*. 2009;459(7249):931-9.
11. Hsieh YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, et al. Influenza pandemics: past, present and future. *J Formos Med Assoc*. 2006;105(1):1-6.
12. de Wit E, Fouchier RA. Emerging influenza. *J Clin Virol*. 2008;41(1):1-6.
13. Wright PF, Neumann G, Kawaoka Y. In *Field's Virology*. 5th, editor.: Lippincott, Williams and Wilkins, Philadelphia; 2007.
14. Palese P, Shaw M. In *Field's Virology* 5th, editor.: Lippincott, Williams and Wilkins, Philadelphia; 2007.
15. Julkunen I, Mele'n K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. *Vaccine*. 2001;19:S32-S7.
16. Wu W, Booth JL, Duggan ES, Wu S, Patel KB, Coggeshall KM, et al. Innate immune response to H3N2 and H1N1 influenza virus infection in a human lung organ culture model. *Virology*. 2010; 396:178-88.
17. Chan MCW, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. *Respiratory Research*. 2005;6(135):1-13.

18. Van Reeth K. Cytokines in the pathogenesis of influenza. *Vet Microbiol.* 2000;74(1-2):109-16.
19. Cheung CY, Poon LLM, Lau AS, Luk W, Lau YL, Shortridge KF, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. *Lancet.* 2002;360:1831–37.
20. Veckman V, Osterlund P, Fagerlund R, Melen K, Matikainen S, Julkunen I. TNF-alpha and IFN-alpha enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells. *Virology.* 2006;345(1):96-104.
21. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. *Chest.* 1997;111(5):1306-21.
22. Lee DCW, Lau ASY. Avian influenza virus signaling: implications for the disease severity of H5N1 infection. *Signal Transduction.* 2007;7:64–80.
23. Osterholm MT. Preparing for the next pandemic. *N Engl J Med.* 2005;352(18):1839-42.
24. Nicholson KG, Wood JM, Zambon M. Influenza. *Lancet.* 2003;362(9397):1733-45.
25. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. *J Infect Dis.* 2005;192(4):665-72.
26. Skeik N, Jabr FI. Influenza viruses and the evolution of avian influenza virus H5N1. *Int J Infect Dis.* 2008;12(3):233-8.
27. Griffiths PD. A perspective on antiviral resistance. *J Clin Virol.* 2009;46(1):3-8.

28. Wong SS, Yuen KY. Avian influenza virus infections in humans. *Chest*. 2006;129(1):156-68.
29. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *N Engl J Med*. 1999;341(18):1336-43.
30. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. *JAMA*. 2001;285(6):748-54.
31. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. *J Infect Dis*. 1998;178(5):1257-62.
32. Butler D. WHO urges regional offices to stockpile flu drug for staff. *Nature*. 2005;436(7053):899.
33. Stiver G. The treatment of influenza with antiviral drugs. *CMAJ*. 2003;168(1):49-57.
34. Itoh T, Ohguchi K, Iinuma M, Nozawa Y, Akao Y. Inhibitory effect of xanthonolones isolated from the pericarp of *Garcinia mangostana* L. on rat basophilic leukemia RBL-2H3 cell degranulation. *Bioorg Med Chem*. 2008;16(8):4500-8.
35. Jiang DJ, Dai Z, Li YJ. Pharmacological effects of xanthonolones as cardiovascular protective agents. *Cardiovasc Drug Rev*. 2004;22(2):91-102.
36. Peres V, Nagem TJ, de Oliveira FF. Tetraoxygenated naturally occurring xanthonolones. *Phytochemistry*. 2000;55(7):683-710.

37. Nakatani K, Atsumi M, Arakawa T, Oosawa K, Shimura S, Nakahata N, et al. Inhibitions of histamine release and prostaglandin E2 synthesis by mangosteen, a Thai medicinal plant. *Biol Pharm Bull.* 2002;25(9):1137-41.
38. Nakatani K, Nakahata N, Arakawa T, Yasuda H, Ohizumi Y. Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. *Biochem Pharmacol.* 2002;63(1):73-9.
39. Kushiro M, Masaoka T, Hageshita S, Takahashi Y, Ide T, Sugano M. Comparative effect of sesamin and episesamin on the activity and gene expression of enzyme in fatty acid oxidation and synthesis in rat liver. *The journal of nutritional biochemistry.* 2002;13:289-95.
40. ศัลยา คงสมบูรณ์เวช. เซซามินกับสุขภาพ. *วารสารโภชนบำบัด,* 2547;15:98-105.
41. Wu WH, Kang YP, Wang NH, Jou HJ, Wang TA. Sesamin ingestion affects sex hormones, antioxidant status, and blood lipids in postmenopausal women. *The journal of nutrition.* 2006;136:1270-5.
42. Utsunomiya T, Chavali SR, Zhong WW, Forse RA. Effects of sesamin-supplemented dietary fat emulsions on the ex vivo production of lipopolysaccharide-induced prostanoids and tumor necrosis factor alpha in rats. *Am J Clin Nutr.* 2000;72(3):804-8.
43. Hirose N, Inoue T, Nishihara K, Sugano M, Akimoto K, Shimizu S, et al. Inhibition of cholesterol absorption and synthesis in rats by sesamin. *J Lipid Res.* 1991;32(4):629-38.

44. Nakano D, Itoh C, Takaoka M, Kiso Y, Tanaka T, Matsumura Y. Antihypertensive effect of sesamin. IV. Inhibition of vascular superoxide production by sesamin. *Biol Pharm Bull.* 2002;25(9):1247-9.
45. Akimoto K, Kitagawa Y, Akamatsu T, Hirose N, Sugano M, Shimizu S, et al. Protective effects of sesamin against liver damage caused by alcohol or carbon tetrachloride in rodents. *Ann Nutr Metab.* 1993;37(4):218-24.
46. Yamashita K, Nohara Y, Katayama K, Namiki M. Sesame seed lignans and gamma-tocopherol act synergistically to produce vitamin E activity in rats. *J Nutr.* 1992;122(12):2440-6.
47. Jeng KCG, Hou RCW. Sesamin and sesamolin : nature's therapeutic lignans. *Current Enzyme Inhibition.* 2005;1:11-20.
48. กลุ่มพืชสมุนไพรและเครื่องเทศ. ขาจากพืชสมุนไพร ชุดที่ 2. คู่มือพืชสมุนไพรและเครื่องเทศ, 2543.
49. Varma A, Padh H, Shrivastana N. Andrographolide: A new plant-derived antineoplastic entity on horizon. *eCAM.* 2009:1-9.
50. Abu-Ghefreh AA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide. *Int Immunopharmacol.* 2009;9(3):313-8.
51. Tsai HR, Yang LM, Tsai WJ, Chiou WF. Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. *European Journal of Pharmacology.* 2004; 498:45– 52.
52. Siddhuraju P BK. Antioxidant properties of various solvent extracts of total phenolic constituents from three different agroclimatic origins of drumstick tree (*Moringa oleifera* Lam.) leaves. *J Agric Food Chem.* 2003;51(8):2144-55.

53. Anwar F, Latif S, Ashraf M, Gilani AH. *Moringa oleifera*: A Food Plant with Multiple Medicinal Uses. *Phytother Res.* 2007;21:17–25.
54. Ndiaye M, Dieye AM, Mariko F, Tall A, Sall Diallo A, Faye B. [Contribution to the study of the anti-inflammatory activity of *Moringa oleifera* (moringaceae)]. *Dakar Med.* 2002;47(2):210-2.
55. Ghasi S, Nwobodo E, Ofili JO. Hypocholesterolemic effects of crude extract of leaf of *Moringa oleifera* Lam in high-fat diet fed wistar rats. *J Ethnopharmacol.* 2000;69(1):21-5.
56. Pal SK, Mukherjee PK, Saha BP. Studies on the antiulcer activity of *Moringa oleifera* leaf extract on gastric ulcer models in rats. *Phytother Res.* 1995;9:463–5.
57. Caceres A, Cabrera O, Morales O, Mollinedo P, Mendia P. Pharmacological properties of *Moringa oleifera*. 1: Preliminary screening for antimicrobial activity. *J Ethnopharmacol.* 1991;33(3):213-6.
58. Murakami A, Kitazono Y, Jiwajinda S, Koshimizu K, Ohigashi H. Niaziminin, a thiocarbamate from the leaves of *Moringa oleifera*, holds a strict structural requirement for inhibition of tumor-promoter-induced Epstein-Barr virus activation. *Planta Med.* 1998;64(4):319-23.
59. Park E, Kum S, Wang C, Park SY, Kim BS, Schuller-Levis G. Anti-inflammatory activity of herbal medicines: inhibition of nitric oxide production and tumor necrosis factor-alpha secretion in an activated macrophage-like cell line. *Am J Chin Med.* 2005;33(3):415-24.
60. Ho JC. The bioactivities of the essential oil and crude extracts from *Houttuynia cordata*. *Hsinchu.* 2007:496-500.

61. Lu H, Wu X, Liang Y, Zhang J. Variation in chemical composition and antibacterial activities of essential oils from two species of *Houttuynia* THUNB. *Chem Pharm Bull (Tokyo)*. 2006;54(7):936-40.
62. Dong Q, Jia LM, Fang JN. A β -D-glucan isolated from the fruiting bodies of *Herichium erinaceus* and its aqueous conformation. *Carbohydrate Research*. 2006;341:791–5.
63. Lee JS, Cho JY, Hong EK. Study on macrophage activation and structural characteristics of purified polysaccharides from the liquid culture broth of *Herichium erinaceus*. *Carbohydrate Polymers*. 2009;78:162–8.
64. Malinowska E, Krzyczkowski W, Herolda F, Łapienis G, Ślusarczyk J, Suchocki P, et al. Biosynthesis of selenium-containing polysaccharides with antioxidant activity in liquid culture of *Herichium erinaceum*. *Enzyme and Microbial Technology*. 2009;44:334–43.
65. Wang Z, Luo D, Liang Z. Structure of polysaccharides from the fruiting body of *Herichium erinaceus* Pers. *Carbohydrate Polymers*. 2004;57:241–7.
66. Phitak T, Choocheep K, Pothacharoen P, Pompimon W, Premanode B, Kongtawelert P. The effects of p-hydroxycinnamaldehyde from *Alpinia galanga* extracts on human chondrocytes. *Phytochemistry*. 2009;70(2):237-43.
67. Phan PV, Sohrabi A, Polotsky A, Hungerford DS, Lindmark L, Frondoza CG. Ginger extract components suppress induction of chemokine expression in human synoviocytes. *J Altern Complement Med*. 2005;11(1):149-54.
68. Grzanna R, Lindmark L, Frondoza CG. Ginger an herbal medicinal product with broad anti-inflammatory actions. *J Med Food*. 2005;8(2):125-32.

69. Brincks EL, Kucaba TA, Legge KL, Griffith TS. Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells. *Hum Immunol.* 2008;69(10):634-46.
70. Boeuf P, Vigan-Womas I, Jublot D, Loizon S, Barale JC, Akanmori BD, et al. CyProQuant-PCR: a real time RT-PCR technique for profiling human cytokines, based on external RNA standards, readily automatable for clinical use. *BMC Immunol.* 2005;6(1):5.
71. Provenzano M, Mocellin S, Bonginelli P, Nagorsen D, Kwon SW, Stroncek D. Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR). *J Transl Med.* 2003;1(1):12.
72. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-Delta C(T)} method. *Methods.* 2001;25(4):402-8.
73. Reiko S, Kazumichi K, Toshikatsu S, Rieko G, Kenji O, Kazufumi S. Anti-influenza virus activity of *Chaenomeles sinensis*. *J Ethnopharmacol.* 2008;118:108-12.
74. Liu AL, Liu B, Qin HL, Lee SM, Wang YT, Du GH. Anti-influenza virus activity of flavonoids from the medicinal plant *Elsholtzia rugulosa*. *Planta Med.* 2008;74:847-51.